Edison Investment Research - mic (M3B) mic - Reverse takeover of Pyramid Computer

Report

Edison Investment Research

Richard Williamson

mic - Reverse takeover of Pyramid Computer

mic has announced the reverse takeover of Pyramid Computer, subject to full financing requirements. Pyramid is active in the high-growth market of digital kiosk solutions and expects to realise revenues of €55m in 2020 and EBIT of €4m. mic expects to surpass estimated market growth of >10% per year by adding selective acquisitions and entering new market segments.

12/11/2020 2 EN

Underlying

mic

See profile

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Richard Williamson

Other Reports on these Companies

Edison Investment Research

mic - Termination of coverage

Edison Investment Research is terminating coverage on: • 2G Energy (2GB) • Apontis Pharma (APPH) • Artec technologies (A6T) • Beta Systems (BSSA) • Blue Cap (B7E) • Cyan (CYR) • Consus Real Estate (CC1) • Daldrup & Soehne (4DS) • DATAGROUP (D6H) • Datron (DAR) • Delignit (DLX) • Deutsche Börse (DB1) • Deutsche Grundstücksauktionen (DGR) • Deutsche Rohstoff (DR0) • DVS Technology (DIS) • Edel (EDL) • Ernst Russ (HXCK) • Exasol (EXL) • expert.ai (EXAI/EXSY) • Fashionette (FSNT) • Formycon (FYB) • Forward Industries (FORD) • Helma Eigenheimbau (H5E) • IBU-tec (IBU) • JDC Group (JDC) • Lloyd Fon...

April 6, 2022 April 6, 2022 1 EN

Edison Investment Research

mic - Stepping up a gear

In FY21, mic AG successfully transformed from a holding company into an operational company active in the point-of-sale market after the acquisition of Pyramid Computer and faytech. Following these acquisitions mic AG changed its name to Pyramid AG at its EGM on 4 March 2022. The company expects revenue of around €100m in FY22 and an EBIT margin of 9%. For subsequent years, it expects double-digit revenue growth, driven by market growth, customer wins and new market segments such as travel, mobility and healthcare. Based on consensus estimates, Pyramid is valued at a discount to its peer group...

March 29, 2022 March 29, 2022 1 EN

Edison Investment Research

mic - Rapidly building position in POS market

mic’s reverse takeover of Pyramid Computer was finalised in June and the company has already announced plans for another large acquisition for further expansion in the point-of-sale (POS) market. Pro-forma revenues, including faytech’s contribution, are expected to amount to €100m in FY22, conditional on completion of this acquisition. Pyramid’s outlook for FY21 is for modest growth in revenues and EBIT, due to current economic conditions.

August 5, 2021 August 5, 2021 1 EN

Northern Data Group - Continued progress as a diversified HPC provider

Northern Data Group demonstrated progress made in Q124 alongside a capital markets day update, as it takes further steps in becoming a diversified high-performance computing (HPC) infrastructure solutions provider. It expects to deploy 20,000 NVIDIA H100 graphic processing units in FY24, cementing its position as Europe’s foremost AI hardware cluster. Key to this, 85% of its H100 capacity has already been sold. Management’s ambitious guidance is unchanged, expecting revenue of €200–240m in FY24 and €520–570m in FY25, with adjusted EBITDA growing from €50–80m in FY24 to €300–350m in FY25. The s...

17h / 40m 17h / 40m 1 EN

Sean Conroy

Sean Conroy

Oryzon Genomics - Doubling down on clinical activity in 2024

Oryzon’s Q124 results emphasised the company’s focus on advancing and expanding its CNS and oncology pipelines, driven by its core assets, vafidemstat and iadademstat. Operating performance was in line, with the lower opex (37% y-o-y decline to €3.2m) driven by reduced R&D spending following completion of the Phase IIb PORTICO trial. Notwithstanding the mixed PORTICO results in borderline personality disorder (BPD), we expect clinical activity to pick up in the coming months, with the initiation of the iadademstat combination studies in first-line AML (Phase Ib) and SCLC (Phase Ib/II) in Q224,...

17h / 53m 17h / 53m 1 EN

Toby Thorrington

Toby Thorrington

AVAX - Strong pipeline reaffirmed

AVAX’s FY23 results highlight the group’s progress domestically as the market improved, more than offsetting the weaker international performance at the top-line and EBITDA level. We have downgraded our 2024 EPS estimates to reflect guidance on continued construction project delays. However, our forecasts incorporate a substantial y-o-y increase in profits, with both PBT and net income more than doubling, bolstered by a record order book of €3.3bn. Our fair value stands at €3.0/share (€3.2/share previously), indicating more than 100% upside potential.

19h / 3m 19h / 3m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

mic - Reverse takeover of Pyramid Computer

mic - Termination of coverage

mic - Stepping up a gear

mic - Rapidly building position in POS market

Northern Data Group - Continued progress as a diversified HPC provider

Oryzon Genomics - Doubling down on clinical activity in 2024

AVAX - Strong pipeline reaffirmed

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe